Gepirone: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 47: Line 47:


==Synthesis==
==Synthesis==
[[
[[File:Gepirone synth.png|800px]]
File:Gepirone synth.png|800px]]


Ormaza, V. A.; 1986, {{Cite patent|ES|8606333}}.
Ormaza, V. A.; 1986, {{Cite patent|ES|8606333}}.

Revision as of 19:51, 17 February 2015

Gepirone
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
Elimination half-life2-3 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H29N5O2
Molar mass359.46586 g/mol
3D model (JSmol)
  (verify)

Gepirone (Ariza, Variza; BMY-13,805, ORG-13,011) is an antidepressant and anxiolytic of the azapirone class. Like other azapirones, it acts as a selective partial agonist of the 5-HT1A receptor. Gepirone was under development in the U.S. in an extended release form, but despite completing phase III clinical trials, it failed to pass the drug approval process. As a result, gepirone, despite already having brand names picked out, did not manage to reach the pharmaceutical market.

Gepirone was originally developed by Bristol-Myers Squibb, but was out-licensed to Fabre-Kramer in 1993. The U.S. Food and Drug Administration (FDA) rejected approval for gepirone in 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2004. However, in 2007 it once again failed to convince the FDA of its qualities for treating anxiety and depression. There have been no updates on gepirone since.

Synthesis

Ormaza, V. A.; 1986, ES 8606333 .

References

Template:Anxiolytics Template:Antidepressants